IBRX Stock Summary and Trading Ideas (Immunitybio | NASDAQ:IBRX)

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

Immunitybio trades on the NASDAQ stock market under the symbol IBRX.

As of January 16, 2026, IBRX stock price climbed to $5.52 with 151,048,302 million shares trading.

IBRX has a beta of 1.73, meaning it tends to be more sensitive to market movements. IBRX has a correlation of 0.07 to the broad based SPY ETF.

IBRX has a market cap of $5.44 billion. This is considered a Mid Cap stock.

Last quarter Immunitybio reported $32 million in Revenue and -$.07 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.03.

In the last 3 years, IBRX traded as high as $10.53 and as low as $1.21.

The top ETF exchange traded funds that IBRX belongs to (by Net Assets): XBI, VTI, IWM, VB, IBB.

IBRX has outperformed the market in the last year with a price return of +81.6% while the SPY ETF gained +18.1%. IBRX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +118.2% and +173.3%, respectively, while the SPY returned +5.0% and +1.2%, respectively.

IBRX support price is $3.74 and resistance is $4.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IBRX shares will trade within this expected range on the day.